

**Company Number: 400279**

**Rafferty Chemists Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 30 April 2025**

## **Rafferty Chemists Limited**

# **CONTENTS**

	<b>Page</b>
Directors' Responsibilities Statement	3
Balance Sheet	4 - 5
Notes to the Financial Statements	6 - 10

# Rafferty Chemists Limited

## DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 April 2025

The directors made the following statement in respect of the unaudited financial statements:

### "General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently.
- make judgements and accounting estimates that are reasonable and prudent.
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them.

The directors confirm that they have made available to Azets Ireland Limited, all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 30 April 2025."

### Signed on behalf of the board

Signed by:

  
Neil Rafferty

Director

10 August 2025

Signed by:

  
John Rafferty

Director

10 August 2025

## Rafferty Chemists Limited

### BALANCE SHEET

as at 30 April 2025

	Notes	2025 €	2024 €
<b>Fixed Assets</b>			
Tangible assets	7	69,851	51,236
Investments	8	422,280	718,995
<b>Fixed Assets</b>		<u>492,131</u>	<u>770,231</u>
<b>Current Assets</b>			
Stocks	9	589,485	568,330
Debtors	10	489,762	410,445
Cash and cash equivalents		1,779,864	1,640,678
		<u>2,859,111</u>	<u>2,619,453</u>
<b>Creditors: amounts falling due within one year</b>	11	<u>(479,977)</u>	<u>(496,617)</u>
<b>Net Current Assets</b>		<u>2,379,134</u>	<u>2,122,836</u>
<b>Total Assets less Current Liabilities</b>		<u>2,871,265</u>	<u>2,893,067</u>
<b>Capital and Reserves</b>			
Called up share capital presented as equity		100	100
Retained earnings		2,871,165	2,892,967
<b>Shareholders' Funds</b>		<u>2,871,265</u>	<u>2,893,067</u>

## Rafferty Chemists Limited BALANCE SHEET

as at 30 April 2025

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Rafferty Chemists Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

**Approved by the board on 10 August 2025 and signed on its behalf by:**


Signed by:



~~Neil Rafferty~~ E...

Director

Signed by:



~~John Rafferty~~ E...

Director

# Rafferty Chemists Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

### 1. General Information

Rafferty Chemists Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 400279. The registered office of the company is Century House, Harolds Cross Road, Dublin 6W. The company operates retail pharmacies at Stillorgan Shopping Centre and Cornelscourt Shopping Centre in Dublin. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the financial year ended 30 April 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

#### Going concern

The financial statements have been prepared on the going concern basis.

#### Goodwill

Purchased goodwill arising on the acquisition of a business represents the excess of the acquisition cost over the fair value of the identifiable net assets including other intangible fixed assets when they were acquired. Purchased goodwill is capitalised in the Balance Sheet and amortised on a straight line basis over its economic useful life of 10 years, which is estimated to be the period during which benefits are expected to arise. On disposal of a business any goodwill not yet amortised is included in determining the profit or loss on sale of the business.

#### Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Long leasehold property	-	10% Straight line
Fixtures, fittings and equipment	-	15% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Profit and Loss Account in the financial year in which it is receivable.

# Rafferty Chemists Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

### Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

### Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

### Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

### Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

### Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Profit and Loss Account annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Profit and Loss Account when received.

### Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

### Financial Instruments

#### Financial Instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other

## Rafferty Chemists Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in the case of an out-right short-term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Profit & loss account.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

<b>3. Operating loss</b>	<b>2025</b>	2024
	€	€
<b>Operating loss is stated after charging/(crediting):</b>		
Depreciation of tangible assets	<b>19,150</b>	16,765
Government grants received	-	(5,000)
	<u>          </u>	<u>          </u>

<b>4. Income from investments</b>	<b>2025</b>	2024
	€	€
Investment income	<b>10,182</b>	-
	<u>          </u>	<u>          </u>

### 5. Employees

The average monthly number of employees, including directors, during the financial year was 27, (2024 - 27).

	<b>2025</b>	2024
	Number	Number
Management	<b>2</b>	2
Sales	<b>25</b>	25
	<u>          </u>	<u>          </u>
	<b>27</b>	27
	<u>          </u>	<u>          </u>

### 6. Intangible assets

	<b>Goodwill</b>	<b>Total</b>
	€	€
<b>Cost</b>		
At 1 May 2024	<u>1,050,000</u>	<u>1,050,000</u>
At 30 April 2025	<u>1,050,000</u>	<u>1,050,000</u>
<b>Provision for diminution in value</b>		
At 30 April 2025	<u>1,050,000</u>	<u>1,050,000</u>
<b>Net book value</b>		
At 30 April 2025	<u>          </u>	<u>          </u>
	-	-
	<u>          </u>	<u>          </u>

## Rafferty Chemists Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

### 7. Tangible assets

	Long leasehold property €	Fixtures, fittings and equipment €	Total €
<b>Cost</b>			
At 1 May 2024	120,000	468,184	588,184
Additions	-	37,765	37,765
At 30 April 2025	<u>120,000</u>	<u>505,949</u>	<u>625,949</u>
<b>Depreciation</b>			
At 1 May 2024	120,000	416,948	536,948
Charge for the financial year	-	19,150	19,150
At 30 April 2025	<u>120,000</u>	<u>436,098</u>	<u>556,098</u>
<b>Net book value</b>			
At 30 April 2025	<u>-</u>	<u>69,851</u>	<u>69,851</u>
At 30 April 2024	<u>-</u>	<u>51,236</u>	<u>51,236</u>

### 8. Investments

	Other unlisted investments €	Total €
<b>Investments</b>		
<b>Cost</b>		
At 1 May 2024	718,995	718,995
Disposals	(296,715)	(296,715)
At 30 April 2025	<u>422,280</u>	<u>422,280</u>
<b>Net book value</b>		
At 30 April 2025	<u>422,280</u>	<u>422,280</u>
At 30 April 2024	<u>718,995</u>	<u>718,995</u>

### 9. Stocks

	2025 €	2024 €
Finished goods and goods for resale	<u>589,485</u>	<u>568,330</u>

The replacement cost of stock did not differ significantly from the figures shown.

### 10. Debtors

	2025 €	2024 €
Trade debtors	132,178	122,878
Other debtors	-	5,000
Deferred tax asset	35,525	-
Directors' current accounts	-	47,790
Taxation	203,796	117,630
Prepayments	118,263	117,147
	<u>489,762</u>	<u>410,445</u>

continued

## Rafferty Chemists Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

<b>11. Creditors</b>	<b>2025</b>	<b>2024</b>
<b>Amounts falling due within one year</b>	<b>€</b>	<b>€</b>
Amounts owed to credit institutions	874	1,522
Trade creditors	414,500	409,902
Taxation	40,548	46,007
Other creditors	(2,422)	(2,088)
Accruals	26,477	41,274
	<u>479,977</u>	<u>496,617</u>
<b>12. Income Statement</b>	<b>2025</b>	<b>2024</b>
	<b>€</b>	<b>€</b>
At 1 May 2024	2,892,967	3,138,935
Loss for the financial year	(21,802)	(245,968)
At 30 April 2025	<u>2,871,165</u>	<u>2,892,967</u>
<b>13. Capital commitments</b>		
The company had no material capital commitments at the financial year-ended 30 April 2025.		
<b>14. Directors' remuneration</b>	<b>2025</b>	<b>2024</b>
	<b>€</b>	<b>€</b>
Remuneration	488,101	403,820
Pension contributions	474,080	679,079
	<u>962,181</u>	<u>1,082,899</u>
<b>15. Controlling interest</b>		
The Rafferty family control 100% of the share capital in Rafferty Chemists Limited, and they are the ultimate controlling party of the group.		
<b>16. Post-Balance Sheet Events</b>		
There have been no significant events affecting the company since the financial year-end.		
<b>17. Share Capital</b>	<b>2025</b>	<b>2024</b>
	<b>€</b>	<b>€</b>
Allotted, called up and fully paid 100 ordinary shares at €1 each	<u>100</u>	<u>100</u>
<b>18. Approval of financial statements</b>		
The financial statements were approved and authorised for issue by the board of directors on 10 August 2025.		